Drug Evidence Authority Failure Through Analyst Impairment and Evidence Consumption at Amherst State Laboratory

The Amherst drug laboratory operated under the administration of the University of Massachusetts, providing drug evidence analysis for law enforcement agencies in western Massachusetts. The laboratory was one of two state drug labs — the other being the Hinton laboratory in Boston, where Annie Dookhan's fabrication was discovered in 2012 (case 041). While the Dookhan scandal consumed public attention, the Amherst lab continued operating. Farak had been employed at the lab since 2003 and began consuming evidence and reference standard samples almost immediately.

The laboratory maintained chain of custody procedures, instrument calibration logs, and analytical documentation consistent with its operating protocols. No policy or procedure required drug testing or fitness-for-duty monitoring of laboratory personnel who handled controlled substances daily. The assumption that an analyst working with drug evidence was not personally consuming that evidence was embedded in the framework without any verification mechanism. Farak had unsupervised access to both evidence samples and reference standards — the pure drug samples used to calibrate instruments and verify test results.

In January 2013, a coworker at the Amherst lab noticed that evidence samples and reference standards were missing or appeared to have been tampered with. The discovery followed by only months the closure of the Hinton lab due to the Dookhan scandal. Investigation revealed that Farak had been consuming controlled substances from the laboratory for approximately nine years — methamphetamine, cocaine, LSD, ketamine, and other drugs taken from both evidence samples submitted for testing and the laboratory's reference standard supply.

Farak was arrested and subsequently pleaded guilty to evidence tampering and drug possession charges. She described working while impaired, sometimes beginning her day by consuming methamphetamine from the laboratory's supply before conducting analyses. The scope of affected cases extended across her entire tenure — approximately 11,000 drug cases in which Farak had performed or been involved in the analysis. Because she had consumed evidence samples and reference standards, both the integrity of individual test results and the calibration of the instruments she used were compromised.

The gap between the authority of the test result and the condition under which it was produced is physical in this case. The test result asserts that a substance was analyzed and found to contain a specific drug at a specific quantity. The authority of that assertion depends on the evidence sample being intact and the analysis being performed competently. When the analyst has consumed part of the evidence and is impaired during the analysis, both conditions are absent — the substance the test result describes has been partially consumed, and the person generating the result is incapacitated. The test result continues to carry the authority of a laboratory finding because nothing in the documentation reveals the conditions under which it was produced.

No personnel fitness monitoring existed for analysts handling controlled substances. The laboratory verified instrument performance, documented analytical procedures, and maintained chain of custody records — all controls directed at the process and the equipment. No control addressed the condition of the analyst. In an environment where a single person had unsupervised access to drug evidence and drug reference standards, the assumption of analyst fitness was structural and unverified. The quality assurance framework checked everything in the laboratory except the person doing the work.

Farak was sentenced to eighteen months in prison followed by probation with drug treatment. The Amherst laboratory was permanently closed. The Massachusetts Attorney General's office initially resisted broad case dismissals, but in 2018 the state's highest court ordered the dismissal of over 11,000 cases affected by Farak's conduct — following a pattern similar to the Dookhan dismissals but delayed by prosecutorial resistance and incomplete initial disclosure of the scope of Farak's impairment. Post-incident reforms included mandatory personnel fitness monitoring for analysts handling controlled substances and structural changes to evidence access controls requiring dual-person authorization for reference standard access.